This website is intended for US Healthcare Professionals.

CONTact Your MSL

Vepdegestrant (ARV-471)

An investigational, oral PROTAC estrogen receptor (ER) degrader.

Vepdegestrant is currently under investigation. Its safety and effectiveness have not been established.

Vepdegestrant is being co-developed with Pfizer.

Back to Development Programs

Clinical Trial Information

VERITAC-2
Phase 3
Vepdegestrant vs fulvestrant in previously treated ER+/HER- advanced or metastatic breast cancer
VIEW STUDY ON CLINICALTRIALS.GOV
VERITAC-3
Phase 3
Vepdegestrant plus palbociclib vs letrozole plus palbociclib in previously untreated ER+/HER- advanced breast cancer
VIEW STUDY ON CLINICALTRIALS.GOV
TACTIVE-U
Phase 1b/2
An umbrella study of vepdegestrant plus other anticancer therapies in ER+ advanced or metastatic breast cancer
Sub-study A – Vepdegestrant plus abemaciclib
VIEW STUDY ON CLINICALTRIALS.GOV
Sub-study B – Vepdegestrant plus ribociclib
VIEW STUDY ON CLINICALTRIALS.GOV
VIEW CLINICAL TRIAL BROCHURE
Sub-study C – Vepdegestrant plus samuraciclib
VIEW STUDY ON CLINICALTRIALS.GOV
VIEW CLINICAL TRIAL BROCHURE
TACTIVE-K
Phase 1b/2
A phase 1b/2 open-label study of vepdegestrant (ARV-471) in combination with PF-07220060 (a CDK4 inhibitor) in patients with ER+/HER2- advanced or metastatic breast cancer
VIEW STUDY ON CLINICALTRIALS.GOV
VIEW CLINICAL TRIAL BROCHURE
TACTIVE-N
Phase 2
A phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with ER+/HER2- localized breast cancer
VIEW STUDY ON CLINICALTRIALS.GOV
TACTIVE-E
Phase 1b
A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer
VIEW STUDY ON CLINICALTRIALS.GOV
ARV-471-mBC-101
Phase 1/2
Vepdegestrant alone or in combination with palbociclib in ER+/HER2- advanced or metastatic breast cancer
VIEW STUDY ON CLINICALTRIALS.GOV

Mechanism of Action

Proposed MOA of vepdegestrant
Arvinas’ PROTAC® protein degrader technology is investigational. Its safety and effectiveness have not yet been established.

Program Resources

Learn how the proposed MOA of vepdegestrant differs from the MOA of SERDs

Related Links

Vepdegestrant Congress Presentations

Access materials related to vepdegestrant presentations at scientific congresses.

Visit Now
Vepdegestrant Publications

View Arvinas publications about vepdegestrant.

Visit Now
Contact My MSL

Connect with your Medical Science Liaison (MSL).

Visit Now

Arvinas Oncology Medical

You are now leaving arvinasoncologymedical.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

YES, I AM AN HCP

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.

I AM NOT AN HCP